Whalesbook
📉 The Financial Deep Dive
The Numbers
Mankind Pharma's unaudited financial results for Q3 FY2026 presented a mixed and concerning picture. On a standalone basis, revenue remained largely flat, inching down by 0.15% to ₹2,632.68 Cr compared to the prior year. More alarmingly, Profit After Tax (PAT) saw a 2.7% decline to ₹449.47 Cr from ₹462.27 Cr in Q3 FY2025. Operating margins (EBITDA/Revenue) compressed noticeably to 27% from 31%, and net profit margins slipped to 17% from 18%.
The consolidated performance was considerably weaker. Revenue declined by 4.6% year-on-year to ₹3,567.20 Cr. This was partly attributed to discontinued operations, specifically the OTC business, which contributed revenue in the previous comparable period. Consolidated PAT witnessed a stark 20.8% drop to ₹413.88 Cr from ₹520.18 Cr. Consolidated EBITDA margins fell to approximately 24.9% from 27.5%, and net profit margins contracted to 11.6% from 14.1%.
Over the nine months of FY2026:
- Standalone revenue grew by 6.1% to ₹7,839.36 Cr, but PAT declined by 11.1% to ₹1,329.04 Cr.
- Consolidated revenue surged by 18.7% to ₹10,834.71 Cr, largely driven by acquisitions, yet PAT plummeted by 22.5% to ₹1,378.68 Cr.
The Quality
The most significant concern lies in the margin compression across both standalone and consolidated books, indicating rising costs or pricing pressures. The substantial drop in consolidated PAT, exceeding the revenue decline, suggests integration challenges or higher operating expenses post-acquisition. Exceptional items amounting to ₹83.42 Cr (standalone) and ₹106.59 Cr (consolidated) further impacted the bottom line. These included provisions for new Labour Codes and an impairment loss on a Hyderabad project.
On the balance sheet front, standalone debt-to-equity ratio improved to 0.40 from 0.73, and the interest service coverage ratio rose to 4.24 from 3.18, showing better leverage management. However, the standalone current ratio stood at a worrying 0.88, below the critical threshold of 1, suggesting potential short-term liquidity challenges.
The Grill
The management's decision to provide no forward-looking guidance is a major point of caution for investors. The company explicitly noted that comparative periods may not be fully comparable due to the acquisition of Bharat Serums and Vaccines Limited (BSV) on October 23, 2024, and other restatements related to business combinations. While management expressed confidence regarding appeals against disallowances from Income Tax Department proceedings, the lack of clarity on future performance and the complex nature of the reported results make for a difficult investment assessment.